Measurement of anxiety in transgenic mice

Reviews in the Neurosciences

Volumn 11, Issue 1, 2000, Pages 59-74

  Weiss, Scott M ^a   Lightowler, Sean ^a   Stanhope, Kelly J ^a   Kennett, Guy A ^a   Dourish, Colin T ^a  

^a Cerebrus Limited   (United Kingdom)

Author keywords

Anxiety; Behaviour; Genetics; Inbred strains; Knockout; Mouse; Risk assessment; Transgenic

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; BEHAVIOR; CONFERENCE PAPER; FEAR; KNOCKOUT MOUSE; MEASUREMENT; MOUSE; NONHUMAN; PHENOTYPE; PHYSIOLOGY; PRIORITY JOURNAL; SCREENING; SHOCK; TRANSGENIC MOUSE;

EID: 0033989793     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: 10.1515/REVNEURO.2000.11.1.59     Document Type: Conference Paper

References (133)

1. Adamec RE, Shallow T. Lasting effects on rodent anxiety of a single exposure to a cat. Physiol Behav 1993; 54: 101-109.
2. Adams DB. Brain mechanisms for offense, defense and submission. Brain Behav Sci 1979; 2: 201-241.
3. Anisman H, Kokkinidis L, Glazier S, Remington G. Differentiation of response biases elicited by scopolamine and d-amphetamine: effects on habituation. Behav Biol 1976; 18: 401-417.
4. APA. Diagnostic and Statistical Manual of Mental Disorders. 4th Ed. Washington, DC: American Psychiatric Association, 1994.
5. Ashcroft GW, Walker LG, Lyle A. A psychobiological model for panic: including models for the mechanisms involved in the regulation of mood and anxiety and implications for behavioural and pharmacological therapies. In: Leonard BE, Butler J, O'Rourke D, Fahy TJ, eds. Psychopharmacology of Panic. Oxford: Oxford University Press, 1993; 131-143.
6. Belzung C, Agmo A. Naloxone blocks anxiolytic-like effects of benzodiazepines in Swiss but not in Balb/c mice. Psychopharmacology (Berl) 1997; 132: 195-201.
7. Belzung C, Berton F. Further pharmacological validation of the BALB/c neophobia in the free exploratory paradigm as an animal model of trait anxiety. Behav Pharmacol 1997; 8: 541-548.
8. Belzung C, Le Pape G. Comparison of different behavioral test situations used in psychopharmacology for measurement of anxiety. Physiol Behav 1994; 56: 623-628.
9. Belzung C, Misslin R, Vogel E, Dodd RH, Chapoutier G. Anxiogenic effects of methyl-β-carboline-3 carboxylate in a light/dark choice situation. Pharmacol Biochem Behav 1987; 29: 29-33.
10. Blanchard DC, Blanchard RJ, Rodgers RJ. Risk Assessment and Animal Models of Anxiety. In: Olivier B, Mos J, Slangen JL, eds. Animal Models in Psychopharmacology. Basle: Birkhauser Verlag, 1991; 117-134.
11. Blanchard RJ, Blanchard DC. Anti-predator defensive behaviours in a visible burrow system. J Comp Psychol 1989; 103: 72-82.
12. Blanchard RJ, Blanchard DC. Crouching as an index of fear. J Comp Physiol Psychol 1969; 67: 370-375.
13. Blanchard RJ, Blanchard DC, Weiss SM. Ethanol effects in an anxiety/defense test battery. Alcohol 1990; 7: 375-81.
14. Blanchard RJ, Blanchard DC, Weiss SM, Mayer S. Effects of ethanol and diazepam on reactivity to predatory odors. Pharmacol Biochem Behav 1990; 35: 775-780.
15. Blanchard RJ, Rodgers RJ, Weiss SM. The characterization and modelling of antipredator defensive behavior. Neurosci Biobehav Rev 1990; 14: 463-472.
16. Blanchard RJ, Taukulis HK, Rodgers RJ, Magee LK, Blanchard DC. Yohimbine potentiates active defensive responses to threatening stimuli in Swiss-Webster mice. Pharmacol Biochem Behav 1993; 44: 673-681.
17. Blumstein LK, Crawley JN. Further characterization of a simple, automated exploratory model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav 1983; 18: 37-40.
18. Boissier JR, Simon P, Aron C. A new method for rapid screening of minor tranquillizers in mice. Eur J Pharmacol 1968; 4: 145-151.
19. Brown JS, Kalish HI, Farber IE. Conditioned fear as revealed by magnitude of startle response to auditory stimulus. J Exp Psychol 1951; 41: 317-328.
20. Clark DM. Anxiety states: panic and generalized anxiety. In: Hawton K, Salkovkis PM, Kirk J, Clark DM, eds. Cognitive Behaviour Therapy for Psychiatric Problems: A Practial Guide. Oxford: Oxford Medical Publications, 1989; 52-96.
21. Clark LA, Watson D, Reynolds S. Diagnosis and classification of psychopathology: challenges to the current system and future directions. Ann Rev Psychol 1995; 46: 121-153.
22. Cole JC, Rodgers RJ. Ethological evaluation of the effects of acute and chronic buspirone treatment in the murine elevated plus-maze test: comparison with haloperidol. Psychopharmacology 1994; 114: 288-296.
23. Cooper SJ. Benzodiazepine-opiate antagonist interactions in relation to feeding and drinking behavior. Life Sci 1983; 32.
24. Costall B, Hendrie CA, Kelly ME, Naylor RJ. Actions of sulpiride and tiapride in a simple model of anxiety in mice. Neuropharmacology 1987; 26: 195-200.
25. Costall B, Jones BJ, Kelly ME, Naylor RJ, Tomkins DM. Exploration of mice in a black and white test box: validation as a model of anxiety. Pharmacol Biochem Behav 1989; 32: 777-785.
26. Costall B, Kelly ME, Naylor RJ. The anxiolytic and anxiogenic effects of ethanol in a mouse model. J Pharm Pharmacol 1988; 40: 197-202.
27. Crawley JN. Exploratory behavior models of anxiety in mice. Neurosci Biobehav Rev 1985; 9: 37-44.
28. Crawley JN. Neuropharmcological specificity for a simple animal model for the behavioral actions of benzodiazepines. Pharmacol Biochem Behav 1981; 15: 695-699.
29. Crawley JN, Belknap JK, Collins A, Crabbe JC, Frankel W, Henderson N, Hitzemann RJ, Maxson SC, Miner LL, Silva AJ, Wehner JM, Wynshaw-Boris A, Paylor R. Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology (Berl) 1997; 132: 107-124.
30. Crawley JN, Goodwin FK. Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav 1980; 13: 167-170.
31. Crawley JN, Paylor R. A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice. Horm Behav 1997; 31: 197-211.
32. Crawley JN, Skolnick P, Paul SM. Absence of intrinsic antagonistic actions of benzodiazepine antagonists on an exploratory model of anxiety in the mouse. Neuropharmacology 1984; 23: 531-537.
33. Cruz AP, Frei F, Graeff FG. Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol Biochem Behav 1994; 49: 171-176.
34. Cunningham CL, Niehus DR, Malott DH, Prather LK. Genetic differences in the rewarding and activating effects of morphine and ethanol. Psychopharmacology 1992; 107: 385-393.
35. Davis M. Animal models of anxiety based on classical conditioning: the conditioned emotional response (CER) and the fear-potentiated startle effect. Pharmacol Ther 1990; 47: 147-165.
36. Dawson GR, Crawford SP, Collinson N, Iversen SD, Tricklebank MD. Evidence that the anxiolytic-like effects of chlordiazepoxide on the elevated plus maze are confounded by increases in locomotor activity. Psychopharmacology 1995; 118: 316-323.
37. de Angelis L, File SE. Acute and chronic effects of three benzodiazepines in the social interaction anxiety test in mice. Psychopharmacology (Berl) 1979; 64: 127-129.
38. Falls WA, Carlson S, Turner JG, Willott JF. Fear-potentiated startle in two strains of inbred mice. Behav Neurosci 1997; 111: 855-861.
39. File SE. ACTH, but not corticosterone impairs habituation and reduces exploration. Pharmacol Biochem Behav 1978; 9: 161-166.
40. File SE. Animal models for predicting clinical efficacy of anxiolytic drugs: social behaviour. Neuropsychobiology 1985; 13: 55-62.
41. File SE. The validation of animal tests of anxiety -pharmacological implications. Pol J Pharmacol Pharm 1984; 36: 505-512.
42. File SE, Hyde JR. Can social interaction be used to measure anxiety? Br J Pharmacol 1978; 62: 19-24.
43. File SE, Lister RG. beta-CCE and chlordiazepoxide reduce exploratory head-dipping and rearing: no mutual antagonism. Neuropharmacology 1982; 21: 1215-1218.
44. File SE, Peet LA. The sensitivity of the rat corticosterone response to environmental manipulations and to chronic chlordiazepoxide treatment. Physiol Behav 1980; 25: 753-758.
45. File SE, Wardill AG. Validity of head-dipping as a measure of exploration in a modified hole-board. Psychopharmacologia 1975; 44: 53-59.
46. Fowler H. Curiosity and Exploratory Behaviour. New York: Macmillian, 1965.
47. Frith CD, Richardson JTE, Samuel M, Crow TJ, McKenna PJ. The effects of intravenous diazepam and hyoscine upon human memory. Q J Exp Psychol A 1984; 36A: 133-144.
48. Gao B, Cutler MG. Buspirone increases social investigation in pair-housed male mice; comparison with the effects of chlordiazepoxide. Neuropharmacology 1993; 32: 429-437.
49. Gao B, Cutler MG. Effects of acute administration of the 5-HT3 receptor antagonist, BRL 46470A, on the behaviour of mice in a two compartment light-dark box and during social interactions in their home cage and an unfamiliar neutral cage. Neuropharmacology 1992; 31: 743-748.
50. Gao B, Cutler MG. Effects of acute and chronic administration of the antidepressants, imipramine, phenelzine and mianserin, on the social behaviour of mice. Neuropharmacology 1994; 33: 813-824.
51. Gao B, Cutler MG. Effects of acute and subchronic administration of propranolol on the social behaviour of mice; an ethopharmacological study. Neuropharmacology 1992; 31: 749-756.
52. Gao B, Cutler MG. Effects of acute and subchronic administration of ritanserin on the social behaviour of mice. Neuropharmacology 1993; 32: 265-272.
53. 3 receptor antagonist, BRL 46470, on the behaviour of oestrous and dioestrous female mice when encountering male partners. Neuropharmacology 1993; 32: 969-975.
54. Gao B, Cutler MG. Effects of quinpirole on the behaviour shown by mice in the light-dark box and during social interactions. Neuropharmacology 1993; 32: 93-100.
55. 3 receptor antagonist, BRL 46470, on the social behaviour of mice. Neuropharmacology 1992; 31: 207-213.
56. Garcia R, Jaffard R. Changes in synaptic excitability in the lateral septum associated with contextual and auditory fear conditioning in mice. Eur J Neurosci 1996; 8: 809-815.
57. Gardner CR. Distress vocalization in rat pups. A simple screening method for anxiolytic drugs. J Pharmacol Meth 1985; 14: 181-187.
58. Goldberg, R.J. Diagnostic dilemmas presented by patients with anxiety and depression. Am J Med 1995; 98: 278-284.
59. Graeff FG. Neurotransmitters in the dorsal periaqueductal grey and animal models of panic anxiety. In: Briely M, File SE, eds. New Concepts in Anxiety. New York: CRC Press, 1991; 288-307.
60. Gray JA. The Psychology of Fear and Stress. 2nd Ed. Cambridge: Cambridge University Press, 1987.
61. Green S, Hodges H. Animal models of anxiety. In: Willner P, ed. Behavioural Models in Psychopharmacology. 2nd Ed. Cambridge: Cambridge University Press, 1991; 21-49.
62. Grewal SS, Shepherd JK, Bill DJ, Fletcher A, Dourish CT. Behavioural and pharmacological characterisation of the canopy stretched attend posture test as a model of anxiety in mice and rats. Psychopharmacology (Berl) 1997; 133: 29-38.
63. Griebel G. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol Ther 1995; 65: 319-395.
64. Griebel G, Blanchard C, Blanchard RJ. Predator-elicited flight responses in Swiss-Webster mice: an experimental model of panic attack. Prog Neuropsychopharmacol Biol Psychiatry 1996; 20: 185-205.
65. Griebel G, Blanchard DC, Jung A, Lee JC, Masuda CK, Blanchard RJ. Further evidence that the mouse defense test battery is useful for screening anxiolytic and panicolytic drugs: effects of acute and chronic treatment with alprazolam. Neuropharmacology 1995; 34: 1625-1633.
66. Grillon C, Ameli R, Foot M, Davis M. Fear-potentiated startle: relationship to the level of state/trait anxiety in healthy subjects. Biol Psychiatry 1993; 33: 566-574.
67. Groneim MM, Hinrichs JV, Mehwaldt SP. Dose-response analysis of the behavioural effects of diazepam. (I) Learning and memory. Psychopharmacology 1984; 82: 291-295.
68. Handley SL, McBlane JW. An assessment of the elevated X-maze for studying anxiety and anxiety-modulating drugs. J Pharmacol Toxicol Meth 1993; 29: 129-138.
69. Handley SL, Mithani S. Effects of alpha-adrenoceptor agonists and antagonists in a maze exploration model of 'fear'-motivated behaviour. Naunyn Schmiedebergs Arch Pharmacol 1984; 327: 1-5.
70. Hendrie CA. The calls of murine predators activate endogenous analgesia mechanisms in laboratory mice. Physiol Behav 1991; 49: 569-573.
71. Hendrie CA, Neill JC. Exposure to the calls of predators of mice activates defensive mechanisms and inhibits consummatory behaviour in an inbred mouse strain. Neurosci Biobehav Rev 1991; 15: 479-482.
72. Hendrie CA, Weiss SM. The development of an animal model of panic with predictive and face validity. In: Cooper SJ, Hendrie CA, eds. Ethology and Psychopharmacology. 6th Ed. Chichester: John Wiley & Sons Ltd., 1994; 111-132.
73. Hendrie CA, Weiss SM, Eilam D. Behavioural response of wild rodents to the calls of an owl: a comparative study. J Zoological Soc Lond 1998; 245: 439-446.
74. 3 receptor antagonists. Psychopharmacology 1991; 104: 545-551.
75. Hughes RN. Behaviour of male and female rats with free choice of two environments differing in novelty. Anim Behav 1968; 16: 92-96.
76. Hughes RN. Intrinsic exploration in animals - motives and measurement. Behav Process 1997; 41: 213-226.
77. 2C receptor agonists and fluoxetine in a model of panic-like anxiety in rats. Eur Neuropsychopharmacol 1998; 8: 161-168.
78. Jenck F, Moreau JL, Martin JR. Dorsal periaqueductal gray-induced aversion as a simulation of panic anxiety: elements of face and predictive validity. Psychiatry Res 1995; 57: 181-191.
79. Jones BC, Sarrieau A, Reed CL, Azar MR, Mormede P. Contribution of sex and genetics to neuroendocrine adaptation to stress in mice. Psychoneuroendocrinology 1998; 23: 505-517.
80. Kaesermann HP. Stretched attend posture, a non-social form of ambivalence, is sensitive to a conflict-reducing drug action. Psychopharmacology 1986; 89: 31-37.
81. Kemble ED. Novel odours increase defensiveness and inhibit attack behaviour in mice. In: Cooper SJ, Hendrie CA, eds. Ethology and Psychopharmacology. Chichester: John Wiley & Sons Ltd., 1994; 191-201.
82. 1c receptor antagonists. Eur J Pharmacol 1989; 164: 445-454.
83. 1A agonist, on conflict behavior and ambulatory activity in mice: comparison with those of buspirone, tandospirone and diazepam. Jpn J Pharmacol 1994; 64: 273-280.
84. Lang P. Fear reduction and fear behavior. In: Schlein J, ed. Research in Psychotherapy. Washington, DC: American Psychological Association, 1967.
85. Leaton RN, Cassella JV, Borszcz GS. Short-term and long-term habituation of the acoustic startle response in chronic decerebrate rats. Behav Neurosci 1985; 99: 901-912.
86. Lightowler S, Kennett GA, Williamson IJ, Blackburn TP, Tulloch IF. Anxiolytic-like effect of paroxetine in a rat social interaction test. Pharmacol Biochem Behav 1994; 49: 281-285.
87. Lister RG. Ethologically based animal models of anxiety disorders. In: File SE, ed. Psychopharmacology of Anxiolytics and Antidepressants. 7th Ed. New York: Pergamon Press Inc., 1991; 155-185.
88. Lister RG. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 1987; 92: 180-185.
89. Marks IM, Neese RM. Fear and fitness: an evolutionary analysis of anxiety disorders. Ethol Sociobiol 1994; 15: 247-261.
90. Marks MJ, Stitzel JA, Collins AC. Genetic influences on nicotine responses. Pharmacol Biochem Behav 1989; 33: 667-678.
91. Martin JR, Moreau JL, Jenck F, Cumin R. Acute and chronic administration of buspirone fails to yield anxiolytic-like effects in a mouse operant punishment paradigm. Pharmacol Biochem Behav 1993; 46: 905-910.
92. Mathis C, Paul SM, Crawley JN. Characterization of benzodiazepine-sensitive behaviors in the A/J and C57BL/6J inbred strains of mice. Behav Genet 1994; 24: 171-180.
93. Mavissakalian MR, Perel JM. Dose-response characterization of the antipanic effects of imipramine. Psychopharmacol Bull 1994; 30: 171-174.
94. Molewijk HE, van der Poel AM, Mos J, van der Heyden JA, Olivier B. Conditioned ultrasonic distress vocalizations in adult male rats as a behavioural paradigm for screening anti-panic drugs. Psychopharmacology 1995; 117: 32-40.
95. Molewijk HE, Vanderpoel AM, Olivier B. The ambivalent behaviour stretched approach posture in the rat as a paradigm to characterize anxiolytic drugs. Psychopharmacology 1995; 121: 81-90.
96. Montgomery KC. Exploratory behaviour as a function of "similarity" of stimulus situations. J Comp Physiol Psychol 1952; 45: 50-57.
97. Montgomery KC. The relation between fear induced by novelty stimulation and exploratory behaviour. J Comp Physiol Psychol 1955; 48: 245-260.
98. Nashold BS, Wilson WP, Slaughter DG. Sensations evoked by stimulation of the midbrain of man. J Neurosurg 1969; 30: 14-24.
99. Nesbitt MN, Spence MA, Butler K. Behavior in chimeric mice combining differently behaving strains. Behav Genet 1979; 9: 277-287.
100. Nutt DJ, Glue P, Lawson C. The neurochemistry of anxiety: an update. Prog Neuropsychopharmacol Biol Psychiatry 1990; 14: 737-752.
101. Paylor R, Tracy R, Wehner J, Rudy JW. DBA/2 and C57BL/6 mice differ in contextual fear but not auditory fear conditioning. Behav Neurosci 1994; 108: 810-817.
102. Pellow S, Chopin P, File SE, Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Meth 1985; 14: 149-167.
103. Pollack MH, Tesar GE, Rosenbaum JF, Spier SA. Clonazepam in the treatment of panic disorder and agoraphobia: a one-year follow-up. J Clin Psychopharmacol 1986; 6: 302-304.
104. Pollard GT, Howard JL. Effects of chlordiazepoxide, pentobarbital, buspirone, chlorpromazine, and morphine in the stretched attend posture (SAP) test. Psychopharmacology 1988; 94: 433-434.
105. Poschel BP. A simple and specific screen for benzodiazepine-like drugs. Psychopharmacologia 1971; 19: 193-198.
106. Przewlocka B, Vetulani J, Lason W, Dziedzicka M, Silberring J, Castellano C, Przewlocki R. The difference in stress-induced analgesia in C57BL/6 and DBA/2 mice: a search for biochemical correlates. Pol J Pharmacol Pharm 1988; 40: 497-506.
107. 1A agonists disrupt memory of fear conditioning in mice. Biol Psychiatry 1993; 33: 247-254.
108. Radulovic J, Kammermeier J, Spiess J. Relationship between fos production and classical fear conditioning: effects of novelty, latent inhibition, and unconditioned stimulus preexposure. J Neurosci 1998; 18: 7452-7461.
109. Reddy DS, Kulkarni SK. Differential anxiolytic effects of neurosteroids in the mirrored chamber behavior test in mice. Brain Res 1997; 752: 61-71.
110. Rocca P, Fonzo V, Scotta M, Zanalda E, Ravizza L. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand 1997; 95: 444-450.
111. Rodgers RJ. Animal models of 'anxiety': where next? Behav Pharmacol 1997; 8: 477-496.
112. Rodgers RJ, Cole JC. Anxiety enhancement in the murine elevated plus maze by immediate prior exposure to social stressors. Physiol Behav 1993; 53: 383-388.
113. Rodgers RJ, Cole JC. The elevated plus-maze: pharmacology, methodology and ethology. In: Cooper SJ, Hendrie CA, eds. Ethology and Psychopharmacology. 6th Ed. Chichester: John Wiley & Sons Ltd., 1994; 10-44.
114. Rodgers RJ, Cole JC. Influence of social isolation, gender, strain, and prior novelty on plus-maze behaviour in mice. Physiol Behav 1993; 54: 729-736.
115. Sano K, Sekino H, Mayanagi. Results of stimulation and destruction of posterior hippocampus in cases with violent, aggressive and restless behaviours. In: Hitchcoch E, Laitinen L, Vaernet K, eds. Psychosurgery. Springfield, IL: Thomas, 1972; 57-71.
116. Schmitt P, Sandner G, Karki P. Escape and approach induced by brain stimulation: a parametric analysis. Behav Brain Res 1981; 2: 49-79.
117. Shehi M, Patterson WM. Treatment of panic attacks with aprazolam and propranolol. Am J Psychopharmacol 1984; 141: 900-901.
118. Shephard RA, Broadhurst PL. Effects of diazepam and picrotoxin on hyponeophagia in rats. Neuropharmacology 1982; 21: 771-773.
119. Shepherd JK, Grewal SS, Fletcher A, Bill DJ, Dourish CT. Behavioural and pharmacological characterisation of the elevated "zero-maze" as an animal model of anxiety. Psychopharmacology (Berl) 1994; 116: 56-64.
120. Simon P, Soubrie P. Behavioral studies to differentiate anxiolytic and sedative activity of the tranquilizing drugs. Mod Probl Pharmacopsychiatry 1979; 14: 99-143.
121. Solyom L, Solyom C, Ledwidge B. Fluoxetine in panic disorder. Can J Psychiatry 1991; 36: 378-380.
122. Spier SA, Tesar GE, Rosenbaum JF, Woods SW. Treatment of panic disorder and agoraphobia with clonazepam. J Clin Psychiatry 1986; 47: 238-242.
123. Takahashi N, Miner LL, Sora I, Ujike H, Revay RS, Kostic V, Jackson-Lewis V, Przedborski S, Uhl GR. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Natl Acad Sci USA 1997; 94: 9938-9943.
124. Toubas PL, Abla KA, Cao W, Logan LG, Seale TW. Latency to enter a mirrored chamber: a novel behavioral assay for anxiolytic agents. Pharmacol Biochem Behav 1990; 35: 121-126.
125. Treit D. Animal models for the study of anti-anxiety agents: a review. Neurosci Biobehav Rev 1985; 9: 203-222.
126. Treit D. Animal models of anxiety and anxiolytic drug action. In: den Boer JA, Ad Stisen JM, eds. Handbook of Depression and Anxiety: A Biological Approach. 8th Ed. New York: Marcel Dekker, 1994; 201-224.
127. Treit D, Fundytus M. A comparison of buspirone and chlordiazepoxide in the shock-probe/burying test for anxiolytics. Pharmacol Biochem Behav 1988; 30: 1071-1075.
128. Treit D, Fundytus M. Thigmotaxis as a test for anxiolytic activity in rats. Pharmacol Biochem Behav 1988; 31: 959-962.
129. Treit D, Menard J, Royan C. Anxiogenic stimuli in the elevated plus-maze. Pharmacol Biochem Behav 1993; 44: 463-469.
130. Trullas R, Skolnick P. Differences in fear motivated behaviors among inbred mouse strains. Psychopharmacology 1993; 111: 323-331.
131. Vogel JR, Beer B, Clody DE. A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia 1971; 21: 1-7.
132. Weiss SM, Wadsworth G, Fletcher A, Dourish CT. Utility of ethological analysis to overcome locomotor confounds in elevated maze models of anxiety. Neurosci Biobehav Rev 1998; 23: 265-271.
133. Westenberg HGM, Den Boer JA. Serotonergic Basis of Panic Disorder. Psychopharmacology of Panic. Oxford: Oxford University Press, 1993; 91-109.